Elena Rodriguez-Vieitez1, Stephen F Carter2, Konstantinos Chiotis1, Laure Saint-Aubert1, Antoine Leuzy1, Michael Schöll1, Ove Almkvist3, Anders Wall4, Bengt Långström5, Agneta Nordberg6. 1. Division of Translational Alzheimer Neurobiology, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 2. Division of Translational Alzheimer Neurobiology, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden Wolfson Molecular Imaging Centre, Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, United Kingdom. 3. Division of Translational Alzheimer Neurobiology, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden Department of Psychology, Stockholm University, Stockholm, Sweden Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden. 4. Department of Surgical Sciences, Section of Nuclear Medicine & PET, Uppsala University, Uppsala, Sweden; and. 5. Deparment of Chemistry, Uppsala University, Uppsala, Sweden. 6. Division of Translational Alzheimer Neurobiology, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden Agneta.K.Nordberg@ki.se.
Abstract
UNLABELLED: The PET tracer (11)C-deuterium-L-deprenyl ((11)C-DED) has been used to visualize activated astrocytes in vivo in patients with Alzheimer disease (AD). In this multitracer PET study, early-phase (11)C-DED and (11)C-Pittsburgh compound B ((11)C-PiB) (eDED and ePiB, respectively) were compared as surrogate markers of brain perfusion, and the extent to which (11)C-DED binding is influenced by brain perfusion was investigated. METHODS: (11)C-DED, (11)C-PiB, and (18)F-FDG dynamic PET scans were obtained in age-matched groups comprising AD patients (n = 8), patients with mild cognitive impairment (n = 17), and healthy controls (n = 16). A modified reference Patlak model was used to quantify (11)C-DED binding. A simplified reference tissue model was applied to both (11)C-DED and (11)C-PiB to measure brain perfusion relative to the cerebellar gray matter (R1) and binding potentials. (11)C-PiB retention and (18)F-FDG uptake were also quantified as target-to-pons SUV ratios in 12 regions of interest (ROIs). RESULTS: The strongest within-subject correlations with the corresponding R1 values (R1,DED and R1,PiB, respectively) and with (18)F-FDG uptake were obtained when the eDED and ePiB PET data were measured 1-4 min after injection. The optimum eDED/ePiB intervals also showed strong, significant ROI-based intersubject Pearson correlations with R1,DED/R1,PiB and with (18)F-FDG uptake, whereas (11)C-DED binding was largely independent of brain perfusion, as measured by eDED. Corresponding voxelwise correlations confirmed the ROI-based results. Temporoparietal eDED or ePiB brain perfusion measurements were highly discriminative between patient and control groups, with discriminative ability statistically comparable to that of temporoparietal (18)F-FDG glucose metabolism. Hypometabolism extended over wider regions than hypoperfusion in patient groups compared with controls. CONCLUSION: The 1- to 4-min early-frame intervals of (11)C-DED or (11)C-PiB are suitable surrogate measures for brain perfusion. (11)C-DED binding is independent of brain perfusion, and thus (11)C-DED PET can provide information on both functional (brain perfusion) and pathologic (astrocytosis) aspects from a single PET scan. In comparison with glucose metabolism, early-phase (11)C-DED and (11)C-PiB perfusion appear to provide complementary rather than redundant information.
UNLABELLED: The PET tracer (11)C-deuterium-L-deprenyl ((11)C-DED) has been used to visualize activated astrocytes in vivo in patients with Alzheimer disease (AD). In this multitracer PET study, early-phase (11)C-DED and (11)C-Pittsburgh compound B ((11)C-PiB) (eDED and ePiB, respectively) were compared as surrogate markers of brain perfusion, and the extent to which (11)C-DED binding is influenced by brain perfusion was investigated. METHODS: (11)C-DED, (11)C-PiB, and (18)F-FDG dynamic PET scans were obtained in age-matched groups comprising ADpatients (n = 8), patients with mild cognitive impairment (n = 17), and healthy controls (n = 16). A modified reference Patlak model was used to quantify (11)C-DED binding. A simplified reference tissue model was applied to both (11)C-DED and (11)C-PiB to measure brain perfusion relative to the cerebellar gray matter (R1) and binding potentials. (11)C-PiB retention and (18)F-FDG uptake were also quantified as target-to-pons SUV ratios in 12 regions of interest (ROIs). RESULTS: The strongest within-subject correlations with the corresponding R1 values (R1,DED and R1,PiB, respectively) and with (18)F-FDG uptake were obtained when the eDED and ePiB PET data were measured 1-4 min after injection. The optimum eDED/ePiB intervals also showed strong, significant ROI-based intersubject Pearson correlations with R1,DED/R1,PiB and with (18)F-FDG uptake, whereas (11)C-DED binding was largely independent of brain perfusion, as measured by eDED. Corresponding voxelwise correlations confirmed the ROI-based results. Temporoparietal eDED or ePiB brain perfusion measurements were highly discriminative between patient and control groups, with discriminative ability statistically comparable to that of temporoparietal (18)F-FDG glucose metabolism. Hypometabolism extended over wider regions than hypoperfusion in patient groups compared with controls. CONCLUSION: The 1- to 4-min early-frame intervals of (11)C-DED or (11)C-PiB are suitable surrogate measures for brain perfusion. (11)C-DED binding is independent of brain perfusion, and thus (11)C-DED PET can provide information on both functional (brain perfusion) and pathologic (astrocytosis) aspects from a single PET scan. In comparison with glucose metabolism, early-phase (11)C-DED and (11)C-PiB perfusion appear to provide complementary rather than redundant information.
Authors: Laura L Boles Ponto; David J Moser; Yusuf Menda; Emily L Harlynn; Sean D DeVries; Jacob J Oleson; Vincent A Magnotta; Susan K Schultz Journal: J Neuroimaging Date: 2018-11-21 Impact factor: 2.486
Authors: Murat Bilgel; Lori Beason-Held; Yang An; Yun Zhou; Dean F Wong; Susan M Resnick Journal: J Cereb Blood Flow Metab Date: 2019-02-12 Impact factor: 6.200
Authors: Ming-Kai Chen; Adam P Mecca; Mika Naganawa; Sjoerd J Finnema; Takuya Toyonaga; Shu-Fei Lin; Soheila Najafzadeh; Jim Ropchan; Yihuan Lu; Julia W McDonald; Hannah R Michalak; Nabeel B Nabulsi; Amy F T Arnsten; Yiyun Huang; Richard E Carson; Christopher H van Dyck Journal: JAMA Neurol Date: 2018-10-01 Impact factor: 18.302
Authors: Ming-Kai Chen; Adam P Mecca; Mika Naganawa; Jean-Dominique Gallezot; Takuya Toyonaga; Jayanta Mondal; Sjoerd J Finnema; Shu-Fei Lin; Ryan S O'Dell; Julia W McDonald; Hannah R Michalak; Brent Vander Wyk; Nabeel B Nabulsi; Yiyun Huang; Amy Ft Arnsten; Christopher H van Dyck; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2021-03-24 Impact factor: 6.200
Authors: Fabio Raman; Yu-Hua Dean Fang; Sameera Grandhi; Charles F Murchison; Richard E Kennedy; John C Morris; Parinaz Massoumzadeh; Tammie Benzinger; Erik D Roberson; Jonathan McConathy Journal: J Nucl Med Date: 2021-05-28 Impact factor: 10.057
Authors: Christin Y Sander; Stefano Bovo; Angel Torrado-Carvajal; Daniel Albrecht; Hongping Deng; Vitaly Napadow; Julie C Price; Jacob M Hooker; Marco L Loggia Journal: J Cereb Blood Flow Metab Date: 2021-06-23 Impact factor: 6.960